Alnylam finds belly fat gene and drug target in UK Biobank study
pharmaphorum
JULY 28, 2022
Transgenic mice in which the gene has been deleted have improved control of blood glucose and insulin sensitivity. “We are currently testing this hypothesis, with the goal of pursuing a development candidate targeting INHBE in the near future,” said Paul Nioi, head of Alnylam’s human genetics group.
52 
Let's personalize your content